10.1.3: Rheumatic disease suppressant drugs

Part of chapter 10 Musculoskeletal and Joint Diseases, section 10.1 Drugs used in rheumatic diseases and gout

High-level prescribing trends for Rheumatic disease suppressant drugs (BNF section 10.1.3) across East of England Commissioning Region for the last five years. You can explore prescribing trends for this section by Sub-ICB Location, or learn more about this site.

View all matching dm+d items.

No prescriptions found.

Do you need help with your analysis? Don't forget to check the FAQ page, and get in touch if you have questions.

Chemicals

Abatacept (1001030V0)
Adalimumab (1001030S0)
Anakinra (1001030R0)
Apremilast (1001030AA)
Auranofin (1001030A0)
Baricitinib (1001030AC)
Certolizumab pegol (1001030Y0)
Etanercept (1001030D0)
Filgotinib (1001030AG)
Golimumab (1001030X0)
Hydroxychloroquine sulfate (1001030C0)
Infliximab (1001030T0)
Leflunomide (1001030L0)
Methotrexate (1001030U0)
Penicillamine (1001030F0)
Sarilumab (1001030AD)
Secukinumab (1001030AF)
Sodium aurothiomalate (1001030J0)
Tiopronin (1001030Q0)
Tocilizumab (1001030W0)
Tofacitinib (1001030AB)
Upadacitinib (1001030AE)
Feedback